NASDAQ:PRCT
PROCEPT BioRobotics Corp
PROCEPT BioRobotics Corp's revenue grew 37.2% in fiscal 2025 to $308.1M while operating margin rose to −33.7%, its highest in 6 years. Free cash flow was −$58.3M, −18.9% of revenue, and the diluted share count rose 6.6%.Summary generated from PROCEPT BioRobotics Corp's SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$308.1M
Revenue growth+37.2%
Revenue, 5-yr CAGR+109.0%
Gross margin63.7%
Operating margin−33.7%
Net margin−31.0%
ROIC−65.4%
Return on equity−24.9%
Debt / equity0.14
Free cash flow−$58.3M
FCF margin−18.9%
Share count change+6.6%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 34 | 75 | 136 | 224 | 308 |
| Operating income | −54 | −81 | −109 | −97 | −104 |
| Net income | −60 | −87 | −106 | −91 | −96 |
| Free cash flow | −58 | −83 | −133 | −104 | −58 |
Recent filings
- 4Insider transaction report
Oct 5, 2026 - 8-KDirector or officer change
Oct 2, 2026 - 8-KEntry into a material agreement
Sep 24, 2026 - 4Insider transaction report
Sep 10, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 5, 2026 - 8-KResults of operations and financial condition
Aug 4, 2026 - 8-KResults of a shareholder vote
Jun 10, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
Apr 30, 2026